Early benefit assessment: Reviews and negotiations – Problems and conflicts
When the legislature created the Act on the Restructuring of the Pharmaceutical Market (AMNOG), it included difficult components in terms of a mandatory discount, price moratorium and early benefit assessment that directly and massively impact existing business models. Especially with the procedure of the early benefit assessment, it has established a process that is as complex as it is complicated, and in some places it is questionable from a methodological standpoint.
To facilitate an easier categorization of individual aspects of the procedure, we have developed an interactive information graphic in cooperation with ÄrzteZeitung that illustrates the process of the early benefit assessment, including the parties involved and the resulting problems and conflicts.
Start info graphic as an animation
Download info graphic as a PDF document
Technical information: For optimal representation, this web application requires a modern HTML5-compatible browser. (Firefox, Chrome and Safari Version 4 and later, Opera Version 10 and later, Internet Explorer Version 9 and later, as well as iPad/iPhone browser and various tablet browsers). If you have none of the above browsers, the application is displayed in slightly limited form via Flash Player.
Grafik: Golden Section Graphics – Dirk Aschoff
Konzeption und Produktion: Springer Medizin in co-operation with Franchise-Canada